Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery (SPAR-Breast)

November 10, 2026 updated by: Mahidol University

Dosimetric Comparison of Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery: A Prospective Paired Study

This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).

Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.

In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.

The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.

The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.

Study Overview

Status

Not yet recruiting

Detailed Description

This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.

Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.

The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.

The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.

The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Histologically confirmed breast carcinoma or ductal carcinoma in situ (DCIS)
  • Status post breast-conserving surgery
  • Planned adjuvant breast-only radiotherapy
  • No indication for regional nodal irradiation
  • Preoperative breast size corresponding to bra cup A-B, defined by the patient's preoperative bra size or a bust-minus-underbust circumference difference of <14 cm
  • Age ≥18 years

Exclusion Criteria:

  • Planned treatment using Deep Inspiration Breath Hold (DIBH)
  • Bilateral breast cancer
  • Previous radiotherapy to the ipsilateral breast
  • Unable to tolerate either the prone or supine position
  • Breast volume >750 cm³
  • Pre-existing heart disease or lung disease
  • Active connective tissue disease
  • Pregnant or found to be pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supine and Prone Whole-Breast Radiotherapy Planning

All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability.

Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Heart Dose in Supine Versus Prone Treatment Plans
Time Frame: within 4 weeks after both CT simulations

Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage.

within 4 weeks after both CT simulations
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
Time Frame: within 4 weeks after both CT simulations

Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage.

within 4 weeks after both CT simulations

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTV_Eval V95 in Supine Versus Prone Treatment Plans
Time Frame: within 4 weeks after both CT simulations

PTV_Eval V95, defined as the percentage of PTV_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV_Eval V95 will be compared between the two positions. The unit of measure is percentage (%).

within 4 weeks after both CT simulations
Treatment time from initial setup to treatment completion
Time Frame: within 4 weeks after treatment completion

Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes.

within 4 weeks after treatment completion
translational X Positioning Accuracy
Time Frame: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Y Positioning Accuracy
Time Frame: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Z Positioning Accuracy
Time Frame: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
Patient Satisfaction Score
Time Frame: within 1 hours after both CT simulations, and within 1 hours after treatment completion

Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position.

within 1 hours after both CT simulations, and within 1 hours after treatment completion
Radiation Therapist Satisfaction
Time Frame: within 1 hours after treatment completion

Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique.

within 1 hours after treatment completion
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
Time Frame: Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity.

Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tanun Jitwatcharakomol, MD, Mahidol University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

October 28, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe